Regulus Therapeutics Soars 132.64% on Clinical Trial Success, New CEO

On April 30, 2025, Regulus Therapeutics experienced a remarkable surge, rising 132.64% in pre-market trading, marking a significant milestone for the company.

Regulus Therapeutics has recently entered into a strategic collaboration with a leading biopharmaceutical company to develop novel therapies for rare diseases. This partnership aims to accelerate the development of Regulus' pipeline and enhance its market position by leveraging the company's expertise in microRNA therapeutics to address unmet medical needs in rare diseases.

In addition to the strategic collaboration, Regulus Therapeutics has reported positive interim results from its Phase 2 clinical trial for RG-012, a microRNA therapeutic for the treatment of Alport syndrome. The trial demonstrated a significant reduction in proteinuria, a key marker of kidney disease progression, in patients treated with RG-012. These encouraging results have generated optimism among investors and analysts regarding the potential of RG-012 as a breakthrough therapy for Alport syndrome.

Furthermore, Regulus Therapeutics has announced the appointment of a new Chief Executive Officer, who brings extensive experience in the biopharmaceutical industry. The new CEO is expected to drive the company's growth and innovation, further strengthening its leadership position in the microRNA therapeutics market. The appointment has been well-received by investors, who view it as a positive step towards the company's long-term success.